PARSIPPANY, N.J. - The U.S. Food and Drug Administration on Nov. 16 approved Teva Pharmaceuticals' IGALMI sublingual film as the first at-home treatment for acute agitation in adults with schizophrenia or bipolar disorder.
First At-Home Approval Expands Outpatient Care
IGALMI becomes the first FDA-approved therapy that patients can self-administer outside a supervised healthcare setting. Agitation—sudden episodes of severe restlessness and tension—affects 25% to 40% of patients with schizophrenia and bipolar disorder, according to Teva data cited by Reuters. Teva said in its press release that "With this approval, IGALMI becomes the first FDA-approved treatment that can be used at home for agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults." Teva acquired IGALMI in October 2026 after purchasing nearly all assets of BioXcel Therapeutics.
Phase 3 Trial Confirms 12-Week Tolerability
In the Phase 3 SERENITY At-Home trial, IGALMI treated 1,160 agitation episodes across 102 patients over 12 weeks with consistent repeat-dosing tolerability. Teva reported that the most common adverse events occurring in at least 5% of patients and above placebo were somnolence, dry mouth, dizziness and oral numbness, with zero tolerability-related discontinuations. Psychiatric Times noted that the supplemental New Drug Application for at-home use was submitted on Jan. 14, 2026.
Safety Guidance Sets Eight-Hour Driving Warning
Outpatient use requires strict safety precautions because the drug lowers blood pressure and causes drowsiness. Drug Topics reported that pharmacists must counsel patients to sit or lie down after dosing and avoid driving or operating heavy machinery for at least 8 hours following a dose. Teva said it will announce commercialization plans for at-home IGALMI at a later date.



